This is the authors' abstract. We don't add key points for this paper.
The development of immunotherapies and targeted medicines, and cancer treatment has advanced quickly, giving patients new hope. However, these treatments have a high financial cost, which calls into question their accessibility, value, and cost-effectiveness. This essay examines the intricate economics of oncology, emphasizing the exorbitant expenses, ambiguous worth, and clinical compromises linked to anticancer medications. Anticancer medicine prices have soared, frequently surpassing $100,000 per patient yearly, putting a burden on both individuals and healthcare systems. Although these treatments are expensive, their clinical advantages are yet unknown, and some populations only see slight gains in survival and quality of life. Additionally, the effectiveness of these treatments varies greatly within patient subgroups, and their safety profiles sometimes involve serious side effects. This study evaluates the efficacy of these treatments by combining clinical trial data, economic models, and patient outcome measures. The commercial and regulatory factors that influence drug pricing and innovation are also assessed. The study emphasizes that to guarantee fair and sustainable cancer care, value-based pricing models, increased regulatory oversight, and patientcentered outcome assessments are required. The comprehensive study of these issues is intended to educate legislators, medical professionals, and industry participants in order to promote a wellrounded strategy that balances patient care with economic viability. In order to maximize the clinical benefits of cancer treatment while reducing its financial impact, these challenges must be addressed.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
VS et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: